The Janssen Pharmaceutical Companies of Johnson & Johnson reported updated results from Legend Biotech Inc.'s LEGEND-2 phase I/II open-label study, which evaluated the investigational chimeric antigen receptor T-cell therapy LCAR-B38M in the treatment of patients with advanced relapsed or refractory multiple myeloma.
AstraZeneca and Acerta Pharma, its hematology research and development center of excellence, have presented new, long-term follow-up results for Calquence (acalabrutinib) in patients with relapsed or refractory mantle cell lymphoma and updated results of an ongoing clinical trial assessing acalabrutinib monotherapy in treatment-naïve patients with chronic lymphocytic leukemia at ASH.
Geron Corp. announced that results from IMbark, a phase II clinical trial of imetelstat treatment in Intermediate-II or High-risk myelofibrosis patients who are relapsed or refractory to a Janus Kinase inhibitor, were presented at ASH.
AstraZeneca and Acerta Pharma, its hematology research and development center of excellence, have presented new, long-term follow-up results for Calquence (acalabrutinib) in patients with relapsed or refractory mantle cell lymphoma and updated results of an ongoing clinical trial assessing acalabrutinib monotherapy in treatment-naïve patients with chronic lymphocytic leukemia at ASH.
A new combination of three drugs that harness the body's immune system is safe and effective, destroying most cancer cells in 95 percent of patients with recurrent Hodgkin lymphoma, according to the results of an early-phase study.
Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company, reported positive top-line results from the phase IIb SADAL (Selinexor Against Diffuse Aggressive Lymphoma) study evaluating selinexor, the company's first-in-class, oral Selective Inhibitor of Nuclear Export compound, in patients with relapsed or refractory diffuse large B-cell lymphoma after at least two prior multi-agent therapies and who are ineligible for transplantation, including high dose chemotherapy with stem cell rescue.
Celgene Corp. announced initial data from the dose-escalation part of an ongoing, open-label multicenter phase 1/2 study of investigational lisocabtagene maraleucel (liso-cel; JCAR017) in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma, including patients with cytogenetic features of high-risk disease, who were previously treated with ibrutinib.
The latest results from an ongoing clinical study incorporating the immunotherapy SurVaxM as part of combination treatment for glioblastoma show that the investigational drug is safe, well-tolerated and extended survival even among the hardest-to-treat subgroups of patients.
Merck KGaA, Darmstadt, Germany, and Pfizer Inc. announced the phase III JAVELIN Ovarian 200 trial evaluating avelumab alone or in combination with pegylated liposomal doxorubicin, a type of chemotherapy, compared with PLD did not meet the prespecified primary endpoints of overall survival or progression-free survival in patients with platinum-resistant or -refractory ovarian cancer.
Researchers with Biodesix and Genentech presented findings on a test designed to predict response to atezolizumab (Tecentriq) in patients with non-small cell lung cancer.
